Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Health
Pharmalot
STAT+
The Readout

The lure of staying private & the rise of precision meds

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan March 7, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for March 07, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Academia’s postdoc system is teetering, imperiling efforts to diversify…
Academia’s postdoc system is teetering, imperiling efforts to diversify life sciences
Akero’s NASH drug combined with Ozempic cut liver fat…
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Researching collagen to help his achy knees, a statistician…
Researching collagen to help his achy knees, a statistician explores the painfully weak evidence
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories